Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)
Lymphoma, B-Cell
About this trial
This is an interventional treatment trial for Lymphoma, B-Cell focused on measuring Rituximab, CHOP, Bi-weekly, low-grade B-cell lymphoma, advanced stage, follicular lymphoma, G-CSF, Untreated stage III/IV low-grade B-cell lymphoma
Eligibility Criteria
Inclusion Criteria: Histological confirmed, low-grade B-cell lymphoma except mantle cell lymphoma and histologic transformation to DLBCL CD20-positive Ann Arbor CS III or IV Lymphoma cell count in PB≦10,000/mm3 20<=age<=69 ECOG PS 0-2 Bidimensionally measurable disease >1.5cm in a single dimension by CT scans No prior chemotherapy, radiotherapy, interferon-alfa, or antibody therapy Normal BM, hepatic, renal, cardiac, and pulmonary function Written informed consent Exclusion Criteria: CNS involvement Glaucoma DM treated by insulin Uncontrollable HT AP, AMI Positive HBs antigen seropositive to HCV seropositive to HIV Interstitial pneumonitis, pulmonary fibrosis, or emphysema Severe infection Liver cirrhosis Double cancer Pregnant or lactating Patients who desire auto PBST after CR Patients treated with major tranquilizer or antidepressant
Sites / Locations
- Aichi Medical University
- Aichi Cancer Center Hospital
- Nagoya City University Hospital
- Nagoya University School of Medicine
- Nagoya Daini Red Cross Hospital
- Nagoya Medical Center
- Akita University School of Medicine
- Chiba Cancer Center Hospital
- National Cancer Center Hospital East
- Ehime University Hospital
- University of Fukui Hospital
- School of Medicine,Fukuoka University
- National Kyushu Cancer Center
- National Hospital Organization Kyusyu Medical Center
- University of Occupational and Environmental Health
- Ohta Nishinouchi Hospital
- Gunma University
- Sapporo Hokuyu Hospital
- National Hospital Organization Hokkaido Cancer Center
- Kanazawa Medical University
- Imamura Bun-in Hospital
- Kagoshima University,Faculty of Medicine
- Tokai University School of Medicine
- St.Marianna University School of Medicine,Yokohama City Seibu Hospital
- Kumamoto University Medical School
- NHO Kumamoto Medical Center
- Kyoto Prefectural University of Medicine
- Mie University School of Medicine
- Tohoku University Hospital
- Nagasaki University Hospital
- Nagasaki Medical Center
- Sasebo City General Hospital
- Niigata Cancer Center Hospital
- Oita Prefectural Hospital
- Faculty of Medicine,University of Ryukyus
- Faculty of Medicine, Saga University
- Saitama Cancer Center
- Shiga Medical Center for Adults
- Hamamatsu University School of Medicine
- Tokyo Metropolitan Komagome Hospital
- National Cancer Center Hospital
- Jikei University,Daisan Hospital
- Jikei University Hospital
- Kyorin University School of Medicine
- Tokyo Medical University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
1
2
Rituximab+Standard CHOP
Rituximab+bi-Weekly CHOP